Clinical trials: CD20 Positive
Hematological Tumors
Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors
This is a single-group, open, dose escalation and expansion Phase I clinical study, with phase I being a dose escalation study and Phase II being a dose expansion study.
- Trial name
- NCT05489276
- Testing
- TQB2825 injection
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Recruiting
A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
This trial is a Multicenter, randomized, double-blind, parallel, controlled, and equivalence phase Ⅲ study. Primary objective: The purpose is to compare the objective response rate of H02 (rituximab biosimilar) plus CHOP and…
- Trial name
- NCT05040906
- Testing
- H02+CHOP, Rituxan +CHOP
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Lymphoma
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell…
- Trial name
- NCT02776813
- Testing
- ACTR087, rituximab
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Cogent Biosciences, Inc.
Diffuse Large B-Cell Lymphoma
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus…
- Trial name
- NCT01287741
- Testing
- Rituximab, Obinutuzumab, Cyclophosphamide
- Where
- 235 sites in United States, Argentina and 27 more
- Volunteers
- 1,418 people
- Sponsor
- Hoffmann-La Roche
B-cell Non Hodgkin Lymphoma
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
This is a Phase 1, open-label, multi-center study to evaluate the safety of JMT601 in the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma and to determine the recommended dose for Phase 2 studies…
- Trial name
- NCT06725524
- Testing
- JMT601
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Shanghai JMT-Bio Inc.
Lymphoma, Non-Hodgkin
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
This study is about a medicine called TAK-981 given with rituximab, used to treat adults with relapsed or refractory CD20-positive non-Hodgkin lymphoma. This study has 2 parts.
- Trial name
- NCT04074330
- Testing
- TAK-981, Rituximab
- Where
- 59 sites in United States, Canada and 7 more
- Volunteers
- 38 people
- Sponsor
- Takeda
Diffuse, Large B-Cell, Lymphoma
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
The purpose of this study is to comparing the Efficacy and Safety between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients.
- Trial name
- NCT02867566
- Testing
- IBI301 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
B-cell Lymphoma
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
This 2-arm study was designed to compare the efficacy and safety of bevacizumab (Avastin) in combination with rituximab (MabThera) and CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)…
- Trial name
- NCT00486759
- Testing
- Bevacizumab, Rituximab, CHOP
- Where
- 266 sites in United States, Argentina and 32 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin's Lymphoma
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)
This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has…
- Trial name
- NCT00517049
- Testing
- PRO95780, rituximab
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Follicular Lymphoma, Lymphoma, Follicular
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
This study will treat follicular lymphoma patients who have not received previous treatment with R-CVP. Half of the patients will receive Zevalin after R-CVP and the other half will receive only R-CVP.
- Trial name
- NCT00384111
- Testing
- Zevalin Therapeutic Regimen, R-CVP
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
CD20-positive B Cell Non-Hodgkin Lymphoma
A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas
This open-label, multicenter,dose-escalating phase I study was designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin…
- Trial name
- NCT04103905
- Testing
- Recombinant Humanized Monoclonal Antibody MIL62 Injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
CD20-positive Non-Hodgkin Lymphoma
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
This is a multicenter, single-arm, open, dose-escalation Phase I/II clinical trial, consisting of a dose-escalation phase (accelerated titration phase, 3+3 design) and a dose expansion phase.
- Trial name
- NCT06021678
- Testing
- EX103 injection
- Where
- 4 sites in China
- Volunteers
- 415 people
- Sponsor
- Guangzhou Excelmab Inc.
Lymphocytic Leukemia, Chronic
A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia
This observational study will evaluate the safety and efficacy of rituximab in combination with chemotherapy in first- and second-line treatment of participants with cluster of differentiation 20 (CD20)-positive B-cell chronic…
- Trial name
- CaLLypso (NCT01609023)
- Testing
- Rituximab
- Where
- 9 sites in Greece
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma.
- Trial name
- NCT02213263
- Testing
- PF-05280586, MabThera®
- Where
- 423 sites in United States, Austria and 28 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
Lymphoma
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
This is the first-in-human study with BYON4228, a humanized monoclonal antibody (mAb) directed against SIRPα.
- Trial name
- NCT05737628
- Testing
- BYON4228 + Rituximab
- Where
- 12 sites in Italy, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- Byondis B.V.
Non-hodgkin's Lymphoma
Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma
Primary Outcome Measures: Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ] Secondary Outcome Measures: The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days…
- Trial name
- NCT03456466
- Testing
- TQB2303, Rituximab
- Where
- 2 sites in China
- Volunteers
- 122 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lymphoma, Large B-Cell, Diffuse
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
This is a multicenter China-only study to investigate the PK, efficacy and safety of SC rituximab versus IV rituximab, both in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated…
- Trial name
- NCT04660799
- Testing
- Rituximab IV, Rituximab SC, Cyclophosphamide
- Where
- 8 sites in China
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
B-cell Lymphoma
A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas
CAR-T cell therapy is a type of treatment for people with certain lymphomas. T-cells are white blood cells that help to fight infections. CAR-T cell therapy improves the body's T-cells to help them better fight cancer cells.
- Trial name
- NCT06248086
- Testing
- ASP2802, MA-20
- Where
- Australia
- Volunteers
- 1 people
- Sponsor
- Astellas Pharma Global Development, Inc.